Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sensus Healthcare (SRTS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Sensus Healthcare (SRTS) over the last 10 years, with Q3 2025 value amounting to $24.5 million.

  • Sensus Healthcare's Cash & Equivalents rose 840.06% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 840.06%. This contributed to the annual value of $22.1 million for FY2024, which is 471.75% down from last year.
  • According to the latest figures from Q3 2025, Sensus Healthcare's Cash & Equivalents is $24.5 million, which was up 840.06% from $22.2 million recorded in Q2 2025.
  • Sensus Healthcare's Cash & Equivalents' 5-year high stood at $37.6 million during Q3 2022, with a 5-year trough of $13.7 million in Q1 2021.
  • Over the past 5 years, Sensus Healthcare's median Cash & Equivalents value was $20.5 million (recorded in 2023), while the average stood at $21.9 million.
  • As far as peak fluctuations go, Sensus Healthcare's Cash & Equivalents soared by 14047.76% in 2022, and later crashed by 4547.99% in 2023.
  • Quarter analysis of 5 years shows Sensus Healthcare's Cash & Equivalents stood at $14.5 million in 2021, then skyrocketed by 75.77% to $25.5 million in 2022, then dropped by 9.29% to $23.1 million in 2023, then decreased by 4.72% to $22.1 million in 2024, then rose by 10.87% to $24.5 million in 2025.
  • Its last three reported values are $24.5 million in Q3 2025, $22.2 million for Q2 2025, and $19.1 million during Q1 2025.